Cancer Innovation
Overview
Cancer Innovation is a scientific journal, published since 2022 in English. The journal's country of origin is United Kingdom and its primary focus area is biomedical engineering.
Details
Details
Abbr.
Cancer Innov
Start
2022
End
Continuing
Frequency
Six issues a year
p-ISSN
2770-9191
e-ISSN
2770-9183
Country
United Kingdom
Language
English
Specialty
Biomedical Engineering
Metrics
Metrics
h-index / Ranks: 15514
4
SJR / Ranks: 10538
389
Recent Articles
1.
Xu H, Li B, Lv P, Chen Y, Lin Y, Zhang A, et al.
Cancer Innov
. 2025 Mar;
4(2):e70004.
PMID: 40078362
Background: The mechanism by which ibrutinib, a Bruton's tyrosine kinase inhibitor, can elevate the risk of arrhythmias is not fully elucidated. In this study, we explored how inhibition of off-target...
2.
Zhou C, Xin H, Qian L, Zhang Y, Wang J, Luo J
Cancer Innov
. 2025 Mar;
4(2):e70000.
PMID: 40078361
Background: Colorectal liver metastasis (CRLM) has a poor prognosis, and traditional prognostic models have certain limitations in clinical application. This study aims to evaluate the prognostic value of CT-based habitat...
3.
Zhang A, Fan L, Liu Q, Zuo X, Zhu J
Cancer Innov
. 2025 Mar;
4(2):e70003.
PMID: 40061827
Radiation therapy can be categorised by particle type into photon, proton and heavy ion therapies. Proton radiotherapy is highlighted due to its unique physical properties, such as the Bragg peak...
4.
He H, Wang L, Ma M
Cancer Innov
. 2025 Mar;
4(2):e160.
PMID: 40026873
Background: Lung adenocarcinoma (LUAD) is a highly heterogeneous cancer type with a poor prognosis. Accurate subtype identification can help guide its treatment. The traditional subtype identification methods using a single-omics...
5.
Wang G, Tang S, Chai L, Liang Y, Li T, Bi W, et al.
Cancer Innov
. 2025 Mar;
4(2):e162.
PMID: 40026872
Background: Treatment of osteosarcoma in children remains difficult. The combination of chemotherapy and surgery is the classic treatment for osteosarcoma. With the development of medicine, chemotherapy has also improved greatly....
6.
Hanamatsu Y, Saigo C, Takeuchi T
Cancer Innov
. 2025 Mar;
4(2):e70001.
PMID: 40026871
No abstract available.
7.
Feng K, Yi Z, Xu B
Cancer Innov
. 2025 Feb;
4(2):e159.
PMID: 39981497
Breast cancer (BC) remains a significant threat to women's health worldwide. The oncology field had an exponential growth in the abundance of medical images, clinical information, and genomic data. With...
8.
Xue J, Liu C, Shao J, Wang L, Han Y, Wang J, et al.
Cancer Innov
. 2025 Feb;
4(2):e163.
PMID: 39981496
Background: The predictive value of the neutrophil-to-lymphocyte ratio (NLR) for immune checkpoint inhibitors (ICIs) in various tumors remains uncertain despite its use in forecasting the effectiveness of immunotherapy. The purpose...
9.
Han Y, Zhang X, Miao L, Lin H, Zhuo Z, He J, et al.
Cancer Innov
. 2025 Jan;
4(1):e154.
PMID: 39817252
-acetyltransferase 10 (NAT10) is a nucleolar acetyltransferase with an acetylation catalytic function and can bind various protein and RNA molecules. As the N4-acetylcytidine (ac4C) "writer" enzyme, NAT10 is reportedly involved...
10.
Sun S, Yin S, Huang J, Zhou D, Tan Q, Man X, et al.
Cancer Innov
. 2025 Jan;
4(1):e142.
PMID: 39777116
Background: Identification of risk genes and loci associated with the recurrence and metastasis of breast cancer (BC) is of utmost importance. Genome-wide association studies (GWASs) represent valuable tools for identifying...